Date: 2013-08-23
Type of information: Development agreement
Compound: LNA drug platform
Company: Shire (UK) Santaris Pharma (Denmark)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement:
Action mechanism:
Disease:
Details: * On August 23rd, 2013. Santaris Pharma, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has announced that its long term partner, Shire has extended the existing partnership in the rare genetic disease space. Under the terms of the extended agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development.
Financial terms: Santaris will receive an upfront payment and, consistent with the initial agreement, is eligible for research support, pre-clinical, clinical and sales milestones and royalties on each product emerging from the collaboration.
Latest news:
